Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$49.25

-0.76 (-1.52%)

, PFE

Pfizer

$32.64

-0.435 (-1.32%)

10:22
10/13/16
10/13
10:22
10/13/16
10:22

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

BMY

Bristol-Myers

$49.25

-0.76 (-1.52%)

PFE

Pfizer

$32.64

-0.435 (-1.32%)

COH

Name/ticker changed to Tapestry/TPR

$35.67

-0.86 (-2.35%)

ETFC

E-Trade

$28.71

-0.22 (-0.76%)

DECK

Deckers Brands

$56.25

-4.73 (-7.76%)

  • 27

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 07

    Nov

BMY Bristol-Myers
$49.25

-0.76 (-1.52%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/13/16
GSCO
10/13/16
DOWNGRADE
GSCO
Buy
Bristol-Myers downgraded to Buy from Conviction Buy at Goldman
Goldman analyst Jami Rubin removed Bristol-Myers from the Conviction Buy List and lowered its price target to $67 from $75 saying disappointing CM-26 data adds a greater level of uncertainty to future trials. He continues to believe is well positioned for 2017, and view the shares as very attractive over the long-term.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
PFE Pfizer
$32.64

-0.435 (-1.32%)

08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
COH Name/ticker changed to Tapestry/TPR
$35.67

-0.86 (-2.35%)

09/30/16
09/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Guggenheim. 2. Wal-Mart (WMT) initiated with an Overweight at KeyBanc and a Buy at Guggenheim. 3. Harley-Davidson (HOG) initiated with a Hold at Jefferies. 4. Coach (COH) was initiated with a Buy at Guggenheim while the firm initiated Michael Kors (KORS) with a Neutral. 5. First Solar (FSLR) initiated with a Buy at Williams Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
OTRG
10/13/16
DOWNGRADE
OTRG
Mixed
Coach downgraded to Mixed from Positive at OTR Global
OTR Global downgraded Coach to Mixed following checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers.
10/05/16
KEYB
10/05/16
DOWNGRADE
KEYB
Sector Weight
Vera Bradley downgraded to Sector Weight at KeyBanc
As previously reported, KeyBanc analyst Edward Yruma downgraded Vera Bradley (VRA) to Sector Weight from Overweight, as he sees risk to its earnings. Yruma thinks the brand's reboot has been successful, as reflected by the 20% year-over-year rise in shares, but with gross margins at their highest since 2010, sales need to increase to drive earnings, he tells investors. In the handbag space, Yruma prefers Coach (COH), on which he keeps an Overweight rating.
10/04/16
WELS
10/04/16
NO CHANGE
WELS
Outperform
Coach still has upside as share retaken from Michael Kors, says Wells Fargo
Wells Fargo analyst Ike Boruchow believes that after Coach (COH) posted its first positive North American comp last quarter in over three years that it appears many investors have recently "moved on," viewing the turnaround story as played out. However, he thinks here is a long way to go should the brand continue to execute and finds it interesting that while investors were keenly aware of how much market share Michael Kors (KORS) was stealing over the past seven years, now it "doesn't seem like anyone is paying attention" as Coach finally takes back share at Kors' expense. Boruchow reiterate an Outperform rating and $46-$48 price target range on Coach share.
ETFC E-Trade
$28.71

-0.22 (-0.76%)

09/30/16
SBSH
09/30/16
NO CHANGE
Target $31.5
SBSH
Neutral
Citi 'inclined to fade' September rally in TD Ameritrade
Citi analyst William Katz attributes the 5% September rally in shares of TD Ameritrade (AMTD) to speculation around a possible acquisition of E-Trade (ETFC). The rally in the shares likely discounts the earnings accretion from such a merger, Katz tells investors in a research note. He believes TD Ameritrade shares at current levels leave "no room for a bad outcome," which he defines as the company deciding not to pursue the deal or E-Trade acquiring Scottrade. As such, Katz says he's "inclined to fade the rally" in TD Ameritrade. The analyst has a Neutral rating on the shares with a $31.50 price target. TD Ameritrade is up 2% in early trading to $35.08.
09/30/16
WELS
09/30/16
NO CHANGE
WELS
Multiple companies could pursue Scottrade, says Wells Fargo
After Bloomberg reported that Scottrade is working with an adviser to explore selling itself, and the article mentioned Ameritrade (AMTD) as a potential suitor, Wells Fargo says that Charles Schwab (SCHW) and E-Trade (ETFC) could "also have interest" in Scottrade. The firm says that the deal could be accretive by double digit percentage levels for all of the potential suitors named. However, ti says that Ameritrade "may be the most logical buyer," since E-Trade just closed on an acquisition and Schwab has sought to place less emphasis trading. The firm keeps an Outperform rating on E-Trade and Market Perform ratings on Schwab and TD Ameritrade.
10/13/16
BOFA
10/13/16
DOWNGRADE
Target $33
BOFA
Neutral
E-Trade downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Michael Carrier downgraded E-Trade to Neutral and raised its price target to $33 from $31.
09/26/16
09/26/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Apache (APA) initiated with a Neutral at MUFG. 2. Marriott (MAR) was initiated with a Buy at Goldman while the firm initiated La Quinta (LQ) with a Sell. Goldman also initiated Red Rock Resorts (RRR), Hyatt (H), and Wyndham (WYN) with a Neutral. 3. Charles Schwab (SCHW) was initiated with an Overweight at Morgan Stanley while the firm initiated E-Trade (ETFC) and TD Ameritrade (AMTD) with an Equal Weight. 4. Valvoline (VVV) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
DECK Deckers Brands
$56.25

-4.73 (-7.76%)

10/13/16
SUSQ
10/13/16
DOWNGRADE
Target $49
SUSQ
Negative
Deckers Brands downgraded to Negative at Susquehanna
As reported previously, Susquehanna analyst Sam Poser downgraded Deckers Brands to Negative from Neutral as he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. The analyst also reduced his estimates and believes gross margin improvement will be below expectations. Poser lowered his price target to $49 from $59 on Deckers Brands shares.
08/15/16
TLSY
08/15/16
UPGRADE
TLSY
Outperform
Deckers Brands upgraded to Outperform from Market Perform at Telsey Advisory
08/15/16
08/15/16
UPGRADE

Outperform
Deckers Brands upgraded to Outperform at Telsey Advisory
As previously reported, Telsey Advisory upgraded Deckers to Outperform from Market Perform and raised its price target to $78 from $68. Analyst Kelly Chen said Deck has become more than just a winter story, although she expects weather will not be as unfavorable as it was last year, as new management is implementing real and meaningful changes that can improve sales and profitability, and drive growth over the long term. Chen highlights new and compelling product innovation, a more advanced and disciplined approach to segmenting the product and the distribution, and taking a hard line on driving efficiencies across the organization by reducing unproductive SKUs, improving lead times and closing stores that are not meeting the company's targets.
09/30/16
GUGG
09/30/16
INITIATION
GUGG
Neutral
Deckers Brands initiated with a Neutral at Guggenheim

TODAY'S FREE FLY STORIES

USO

United States Oil Fund

$12.79

0.03 (0.24%)

15:00
01/17/18
01/17
15:00
01/17/18
15:00
Options
Put buying in US Oil Fund ahead of data »

Put buying in US Oil Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
01/17/18
01/17
15:00
01/17/18
15:00
General news
Breaking General news story  »

Dallas Federal Reserve…

HIMX

Himax

$9.87

-0.83 (-7.76%)

14:59
01/17/18
01/17
14:59
01/17/18
14:59
Recommendations
Himax analyst commentary  »

Baird maintains Himax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$263.25

-1.04 (-0.39%)

, QCOM

Qualcomm

$68.25

2.87 (4.39%)

14:51
01/17/18
01/17
14:51
01/17/18
14:51
Periodicals
Broadcom tells Bloomberg FTC review 'immaterial to business' »

In an emailed statement…

AVGO

Broadcom

$263.25

-1.04 (-0.39%)

QCOM

Qualcomm

$68.25

2.87 (4.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

PVG

Pretium Resources

$11.61

-0.04 (-0.34%)

14:45
01/17/18
01/17
14:45
01/17/18
14:45
Options
Pretium Resources call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
01/17/18
01/17
14:45
01/17/18
14:45
General news
Breaking General news story  »

Chicago Federal Reserve…

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

, GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

14:39
01/17/18
01/17
14:39
01/17/18
14:39
Hot Stocks
Google introduces Cloud AutoML to help businesses use machine learning »

In a blog post, Google…

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

CBS

CBS

$59.44

0.01 (0.02%)

, VIAB

Viacom

$31.38

-2.38 (-7.05%)

14:37
01/17/18
01/17
14:37
01/17/18
14:37
Periodicals
Shari Redstone renews push to merge CBS, Viacom, WSJ reports »

Shari Redstone is…

CBS

CBS

$59.44

0.01 (0.02%)

VIAB

Viacom

$31.38

-2.38 (-7.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 15

    Feb

JBHT

J.B. Hunt

$120.64

-0.42 (-0.35%)

14:35
01/17/18
01/17
14:35
01/17/18
14:35
Technical Analysis
Technical Earnings Preview: J.B. Hunt near life highs before earnings »

At time of writing and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$31.91

-0.44 (-1.36%)

14:35
01/17/18
01/17
14:35
01/17/18
14:35
Hot Stocks
Deason reports 6% stake in Xerox, demands disclosure of JV pact with Fujifilm »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
01/17/18
01/17
14:35
01/17/18
14:35
General news
Treasury Action: yields held near highs »

Treasury Action: yields…

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

, VNRX

VolitionRx

$2.95

0.0441 (1.52%)

14:31
01/17/18
01/17
14:31
01/17/18
14:31
Hot Stocks
Analysts stay bullish on Exact Sciences after ASCO abstract prompts pullback »

Shares of Exact Sciences…

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

VNRX

VolitionRx

$2.95

0.0441 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 26

    Feb

  • 29

    Mar

AG

First Majestic

$7.36

0.0106 (0.14%)

14:30
01/17/18
01/17
14:30
01/17/18
14:30
Options
Far upside call buyers in First Magestic as shares trade flat »

Far upside call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$71.16

-0.05 (-0.07%)

14:26
01/17/18
01/17
14:26
01/17/18
14:26
Hot Stocks
Vornado raises dividend to 63c per share »

Vornado Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALX

Alexander's

$379.05

-3.045 (-0.80%)

14:24
01/17/18
01/17
14:24
01/17/18
14:24
Hot Stocks
Alexander's boosts quarterly dividend to $4.50 per share »

Alexander's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$147.07

0.21 (0.14%)

14:22
01/17/18
01/17
14:22
01/17/18
14:22
Hot Stocks
USPTO board says Janssen Oncology patent claims unpatentable »

In a final written…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

LOCO

El Pollo Loco

$10.10

-0.2 (-1.94%)

14:20
01/17/18
01/17
14:20
01/17/18
14:20
Options
Bullish option flow in El Pollo Loco »

Bullish option flow in El…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
01/17/18
01/17
14:20
01/17/18
14:20
General news
Fed's Beige Book said the economy continued to expand »

Fed's Beige Book…

$NSD

NASDAQ Market Internals

14:17
01/17/18
01/17
14:17
01/17/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
01/17/18
01/17
14:16
01/17/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRSP

Crispr Therapeutics

$27.18

-1.34 (-4.70%)

14:12
01/17/18
01/17
14:12
01/17/18
14:12
Recommendations
Crispr Therapeutics analyst commentary  »

Piper says European…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$54.72

0.12 (0.22%)

14:12
01/17/18
01/17
14:12
01/17/18
14:12
Technical Analysis
Technical Earnings Preview: Morgan Stanley near 52-week high before news »

The stock has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

INTC

Intel

$43.14

-0.1 (-0.23%)

14:10
01/17/18
01/17
14:10
01/17/18
14:10
Options
Large block of puts in Intel as shares advance »

Large block of puts in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

WRB

W. R. Berkley

$70.12

0.7 (1.01%)

14:09
01/17/18
01/17
14:09
01/17/18
14:09
Hot Stocks
W. R. Berkley combines professional liability units »

W. R. Berkley announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

ONTX

Onconova

$1.74

-0.0901 (-4.92%)

14:05
01/17/18
01/17
14:05
01/17/18
14:05
Downgrade
Onconova rating change  »

Onconova downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.